[{"id":"610f01eb-c68e-44f8-9b23-e46ae4e5528c","acronym":"GO-TAG","url":"https://clinicaltrials.gov/study/NCT05716009","created_at":"2023-02-08T18:00:15.099Z","updated_at":"2025-02-25T15:27:53.038Z","phase":"Phase 1","brief_title":"Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML","source_id_and_acronym":"NCT05716009 - GO-TAG","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/25/2027","primary_completion_date":" 12/25/2027","study_txt":" Completion: 12/25/2028","study_completion_date":" 12/25/2028","last_update_posted":"2025-02-10"},{"id":"6f7d4152-8883-4202-b09b-1e6eca244083","acronym":"","url":"https://clinicaltrials.gov/study/NCT05233618","created_at":"2023-08-14T10:11:07.430Z","updated_at":"2025-02-25T17:01:40.560Z","phase":"Phase 1","brief_title":"Study of Tagraxofusp for Post-Transplant Maintenance for Patients with CD 123+ AML, MF and CMML (HSCT 002)","source_id_and_acronym":"NCT05233618","lead_sponsor":"Karen Ballen, MD","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elzonris (tagraxofusp-erzs) • SL-701"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-03"},{"id":"9604cfb1-e6e8-49f6-8502-880d232ccb42","acronym":"","url":"https://clinicaltrials.gov/study/NCT03113643","created_at":"2023-08-14T10:10:56.859Z","updated_at":"2024-07-02T16:34:27.434Z","phase":"Phase 1","brief_title":"SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT03113643","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-11"},{"id":"9436a8ff-5aa6-4f94-a70c-ecf2cecaa874","acronym":"NCI-2022-02215","url":"https://clinicaltrials.gov/study/NCT05285813","created_at":"2023-08-14T10:11:07.915Z","updated_at":"2024-07-02T16:34:58.922Z","phase":"Phase 2","brief_title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","source_id_and_acronym":"NCT05285813 - NCI-2022-02215","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vibecotamab (XmAb14045)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"},{"id":"d849c811-e1a4-4e2a-879f-f191f73d4644","acronym":"TCD17197","url":"https://clinicaltrials.gov/study/NCT05086315","created_at":"2023-08-14T10:11:07.011Z","updated_at":"2024-07-02T16:35:00.248Z","phase":"Phase 1/2","brief_title":"First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT05086315 - TCD17197","lead_sponsor":"Sanofi","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bexatamig (IPH6101)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/11/2025","primary_completion_date":" 12/11/2025","study_txt":" Completion: 11/11/2026","study_completion_date":" 11/11/2026","last_update_posted":"2024-05-29"},{"id":"39c3282f-51bb-4fb8-ab95-8b0dcb862709","acronym":"","url":"https://clinicaltrials.gov/study/NCT05506956","created_at":"2023-08-14T10:11:09.789Z","updated_at":"2024-07-02T16:35:00.814Z","phase":"Phase 1","brief_title":"Post-transplant Flotetuzumab for AML","source_id_and_acronym":"NCT05506956","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 10/20/2022","start_date":" 10/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-27"},{"id":"619771d1-d4a0-44c2-8ac6-1aa798882b7f","acronym":"TAGALONG","url":"https://clinicaltrials.gov/study/NCT05442216","created_at":"2023-08-14T10:11:09.139Z","updated_at":"2024-07-02T16:35:06.443Z","phase":"Phase 2","brief_title":"Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents","source_id_and_acronym":"NCT05442216 - TAGALONG","lead_sponsor":"Joshua Zeidner","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-02"},{"id":"ac11fef2-00de-4d70-b80b-5c5887b96c6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05817058","created_at":"2023-08-14T10:11:11.877Z","updated_at":"2024-07-02T16:35:14.822Z","phase":"Phase 1","brief_title":"First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05817058","lead_sponsor":"Affimed GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFM28"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-13"},{"id":"93a602fc-fef4-4ca8-ada5-f9aa24df7e29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720988","created_at":"2023-08-14T10:11:11.619Z","updated_at":"2025-02-25T15:45:00.769Z","phase":"Phase 1","brief_title":"Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05720988","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/03/2024","start_date":" 08/03/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2026","study_completion_date":" 08/03/2026","last_update_posted":"2024-03-08"},{"id":"883417c3-4016-4ca7-adfb-379f14c7fc53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05476770","created_at":"2023-08-14T10:11:09.445Z","updated_at":"2024-07-02T16:35:18.062Z","phase":"Phase 1","brief_title":"Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","source_id_and_acronym":"NCT05476770","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • vincristine • fludarabine IV • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 11/11/2025","primary_completion_date":" 11/11/2025","study_txt":" Completion: 11/11/2027","study_completion_date":" 11/11/2027","last_update_posted":"2024-02-22"},{"id":"f9804601-1b5e-4001-940c-6e9301ecc5f3","acronym":"CP-MGD024-01","url":"https://clinicaltrials.gov/study/NCT05362773","created_at":"2022-05-05T15:53:53.535Z","updated_at":"2024-07-02T16:35:23.328Z","phase":"Phase 1","brief_title":"A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT05362773 - CP-MGD024-01","lead_sponsor":"MacroGenics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGD024"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-17"},{"id":"2e1f45d7-114f-4454-9867-53cc8e8641d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681105","created_at":"2021-01-19T20:46:40.489Z","updated_at":"2024-07-02T16:35:25.698Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","source_id_and_acronym":"NCT04681105","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 05/05/2026","primary_completion_date":" 05/05/2026","study_txt":" Completion: 05/05/2026","study_completion_date":" 05/05/2026","last_update_posted":"2023-12-20"},{"id":"50591c7e-2bb2-4a10-8880-29d3224dc148","acronym":"PEPN1812","url":"https://clinicaltrials.gov/study/NCT04158739","created_at":"2023-12-11T17:16:23.292Z","updated_at":"2024-07-02T16:35:26.619Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04158739 - PEPN1812","lead_sponsor":"Children's Oncology Group","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-12-11"},{"id":"e40ed8d7-48ac-41b5-b29f-5f77dd399916","acronym":"","url":"https://clinicaltrials.gov/study/NCT05032183","created_at":"2023-08-14T10:11:06.622Z","updated_at":"2024-07-02T16:35:33.498Z","phase":"Phase 1/2","brief_title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","source_id_and_acronym":"NCT05032183","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/17/2022","start_date":" 02/17/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-16"},{"id":"8d195ac4-ff45-457f-b006-0abe5f018000","acronym":"","url":"https://clinicaltrials.gov/study/NCT06006403","created_at":"2023-08-23T15:10:48.638Z","updated_at":"2024-07-02T16:35:38.691Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT06006403","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA positive","tags":["IL6 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD123 targeted CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-30"},{"id":"35ca491d-0cc1-434a-914b-6dc84cb52011","acronym":"","url":"https://clinicaltrials.gov/study/NCT05574608","created_at":"2022-10-10T14:05:46.075Z","updated_at":"2024-07-02T16:35:49.544Z","phase":"Phase 1","brief_title":"Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia","source_id_and_acronym":"NCT05574608","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JD023"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2023-04-26"},{"id":"34bea2f2-8a1e-4060-9d83-36b2c4268cbc","acronym":"Study 0314","url":"https://clinicaltrials.gov/study/NCT02268253","created_at":"2021-01-18T10:39:50.644Z","updated_at":"2024-07-02T16:35:52.835Z","phase":"Phase 2","brief_title":"Tagraxofusp (SL-401) in Patients With CMML or MF","source_id_and_acronym":"NCT02268253 - Study 0314","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" PDGFRA • JAK2 • PDGFRB • PCM1","pipe":" | ","alterations":" FGFR1 rearrangement","tags":["PDGFRA • JAK2 • PDGFRB • PCM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elzonris (tagraxofusp-erzs)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 03/07/2023","study_completion_date":" 03/07/2023","last_update_posted":"2023-03-21"},{"id":"b7c01580-5ee3-4f13-b16b-b440889f56d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04678466","created_at":"2023-08-14T10:11:05.005Z","updated_at":"2024-07-02T16:36:09.693Z","phase":"","brief_title":"Flotetuzumab Expanded Access Program","source_id_and_acronym":"NCT04678466","lead_sponsor":"MacroGenics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-05-30"},{"id":"a8d426ea-8842-4fc1-bfee-96024bf6f5ae","acronym":"APVO436","url":"https://clinicaltrials.gov/study/NCT03647800","created_at":"2021-05-26T19:57:54.811Z","updated_at":"2024-07-02T16:36:17.299Z","phase":"Phase 1b","brief_title":"Study of APVO436 in Patients With AML or MDS","source_id_and_acronym":"NCT03647800 - APVO436","lead_sponsor":"Aptevo Research and Development LLC","biomarkers":" FLT3 • RUNX1 • ASXL1 • IL3RA","pipe":" | ","alterations":" ASXL1 mutation • CD123 positive • IL3RA positive","tags":["FLT3 • RUNX1 • ASXL1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASXL1 mutation • CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mipletamig (APVO436)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 06/15/2023","study_completion_date":" 06/15/2023","last_update_posted":"2022-02-10"},{"id":"f26ff57b-a92c-4ad3-b4f7-844a5f91cc83","acronym":"HOVON162AML","url":"https://clinicaltrials.gov/study/NCT05063123","created_at":"2021-09-30T22:53:06.373Z","updated_at":"2024-07-02T16:36:19.229Z","phase":"Phase 2","brief_title":"Study to Assess an Interphase Cycle With Flotetuzumab.","source_id_and_acronym":"NCT05063123 - HOVON162AML","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2021-12-22"},{"id":"3fedea47-3322-47fb-bf06-bb20557b31c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04973618","created_at":"2023-08-14T10:11:06.153Z","updated_at":"2024-07-02T16:36:20.014Z","phase":"Phase 1b","brief_title":"Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML","source_id_and_acronym":"NCT04973618","lead_sponsor":"Aptevo Therapeutics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • mipletamig (APVO436)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2021-12-01"},{"id":"ef9f33ba-d081-412c-af8d-bf768df5b986","acronym":"","url":"https://clinicaltrials.gov/study/NCT02715011","created_at":"2021-01-18T13:16:28.170Z","updated_at":"2024-07-02T16:36:25.083Z","phase":"Phase 1","brief_title":"Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT02715011","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-63709178"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 03/26/2021","primary_completion_date":" 03/26/2021","study_txt":" Completion: 03/26/2021","study_completion_date":" 03/26/2021","last_update_posted":"2021-08-31"},{"id":"e4d83257-c80b-4e1e-8b12-fb24718335d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03739606","created_at":"2021-01-18T18:18:56.025Z","updated_at":"2024-07-02T16:36:37.235Z","phase":"Phase 2","brief_title":"Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer","source_id_and_acronym":"NCT03739606","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/20/2020","start_date":" 10/20/2020","primary_txt":" Primary completion: 10/20/2020","primary_completion_date":" 10/20/2020","study_txt":" Completion: 10/20/2020","study_completion_date":" 10/20/2020","last_update_posted":"2020-12-17"}]